Xu Hairong, Li Yuan, Yu Feng, Liu Weifeng, Hao Lin, Zhang Qing, Niu Xiaohui
Department of Orthopedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Beijing 100871, China.
J Clin Med. 2023 Jan 23;12(3):892. doi: 10.3390/jcm12030892.
Revisions for oncological prosthesis are especially challenging due to the limited bone quantity and poor quality that the patients still possess. The aims of this study were to ask (1) what is the cumulative survival of the Global Modular Replacement System (GMRS) prosthesis after revision? and (2) what are the long-term functional outcomes of these patients?
We retrospectively reviewed 16 patients who developed aseptic loosening of a lower extremity prosthesis. There were nine males and seven females with a mean age of 28 years (range, 14-55 years). The 5-year and 8-year survivorship of the prosthesis were calculated. Function outcome was evaluated according to the score of the Musculoskeletal Tumor Society (MSTS).
At a mean of 90 months follow-up (range, 52-118 months), the cumulative survival of all revision prosthesis was 94% at both 5 and 8 years. There were two prosthesis failures including one infection and one repeated aseptic loosening. At the last follow-up, except for the infection case, 93.3% (14/15) of the patients did not develop repeated aseptic loosening. The mean MSTS score was 27.7 (range, 24-30).
GMRS prosthesis demonstrated significant satisfactory long-term outcomes for revisions of lower extremity oncological prosthesis.
由于患者剩余骨量有限且质量较差,肿瘤假体翻修极具挑战性。本研究旨在探讨:(1)全球模块化置换系统(GMRS)假体翻修后的累积生存率如何?(2)这些患者的长期功能结局如何?
我们回顾性分析了16例发生下肢假体无菌性松动的患者。其中男性9例,女性7例,平均年龄28岁(14 - 55岁)。计算假体的5年和8年生存率。根据肌肉骨骼肿瘤学会(MSTS)评分评估功能结局。
平均随访90个月(52 - 118个月),所有翻修假体在5年和8年时的累积生存率均为94%。有2例假体失败,包括1例感染和1例反复无菌性松动。在最后一次随访时,除感染病例外,93.3%(14/15)的患者未发生反复无菌性松动。MSTS平均评分为27.7(24 - 30)。
GMRS假体在下肢肿瘤假体翻修方面显示出显著令人满意的长期效果。